Axsome Therapeutics: All Eyes On Auvelity Launch
Shares of Axsome Therapeutics have posted a 30% gain so far in 2022. Read more to understand why this stock needs to be watched.
Source: seekingalpha.com
Page 43 - Compass Pathways News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Compass Pathways. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Compass Pathways Today - Breaking & Trending Today
PTSD: Clinical trial examines 'magic' mushrooms as treatment
A Nova Scotia-based company has received Health Canada approval to conduct a clinical trial to determine if psilocybin, a psychedelic compound found in 'magic' mushrooms, can help those with PTSD who are treatment-resistant.
Source: ctvnews.ca
Main Sequence Ventures, Lionheart Ventures back Aussie psychedelics start-up Psylo
Main Sequence Ventures-backed Psylo is developing new therapies to treat mental illness modelled on naturally occurring psychedelics such as psilocybin.
Source: afr.com
Compass Pathways: De-Risked (Still Risky) Psychedelics Play Enters Phase 3 (NASDAQ:CMPS)
Compass shares lost 82% of their value over the past 12 months. Read what this may mean for a company bringing a form of therapy using psychedelic drug psilocybin to market. Read more here.
Source: seekingalpha.com
With Promise of Legalization, Psychedelic Companies Joust Over Future Profits
Cash rich start-ups are filing scores of patent claims on hallucinogens like magic mushrooms. Researchers and patient advocates worry high prices will make the therapies unaffordable.
Source: nytimes.com